Qrons

Company Overview

Snapshot

Founded in January 2016 by Jonah Meer and Ido Merfeld, Qrons is a biotechnology company with 1-10 employees. The company has raised $500,000 across two funding rounds. In February 2025, Qrons completed a reverse merger with First Person, creating a publicly traded entity focused on cognitive wellness and functional beverages.

Business overview

Qrons is a biotechnology company focused on developing biotech products, treatments, and technologies to combat neuronal diseases. The company leverages artificial intelligence (AI), machine learning (ML), molecular biology, stem cells, and tissue engineering. Its core product candidates, QS100 and QS200, are designed for treating traumatic brain injuries, integrating proprietary modified mesenchymal stem cells (MSCs) and smart synthetic material. QS100 is an injury-specific, 3D-printable, implantable MSC-synthetic hydrogel for penetrating brain injuries, while QS200 is an injectable MSC-synthetic hydrogel for concussions. Qrons operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, targeting providers, pharmaceuticals, and biotechnology companies.

Strategic signal

In July 2025, First Person, the company that merged with Qrons, provided a shareholder update indicating a focus on science-backed supplements and functional beverages, with plans for a Reg A capital raise and a new product launch. This signals a strategic shift and expansion into the broader wellness market, leveraging the combined entity's public status and aiming for accelerated growth and product diversification beyond Qrons' initial focus on neuronal injuries.

Company Intelligence Q&A

What was the most significant recent corporate development for Qrons?

In February 2025, Qrons completed a reverse merger with First Person, a cognitive wellness and functional beverage company. This transaction created a new publicly traded entity, positioning the combined company to accelerate growth and expand product distribution in the cognitive health and functional wellness markets.

What is the current strategic focus of the combined entity after the merger?

In July 2025, First Person, the merged entity, announced its focus on science-backed products in supplements and functional beverages. The company is preparing for a Reg A capital raise and plans to launch a new alcohol- and THC-free social tonic.

What was the initial agreement for the reverse merger with First Person?

In October 2024, First Person Ltd. signed a letter of intent to acquire Qrons Inc. in a reverse merger. The agreement involved issuing 8,000 shares of Qrons Series B Convertible Preferred Stock to First Person's shareholders, resulting in First Person's stockholders holding 80.51% of Qrons' common stock post-merger.

What was a key development in Qrons' scientific advisory board in late 2023?

In November 2023, Qrons announced the addition of Professor Shiri Navon-Venezia, a microbiologist and expert in antibiotic resistance, to its Scientific Advisory Board. This appointment was intended to bolster Qrons' research program, particularly in developing treatments for antibiotic-resistant bacterial infections and sepsis.

What was a significant intellectual property development for Qrons in 2023?

In August 2023, Qrons filed a United States Provisional Patent Application for Tellurium Compositions and Techniques for Use Therewith. This patent relates to the therapeutic effect of certain Tellurium-based compounds on antibiotic-resistant bacterial infections, sepsis, and traumatic brain injuries, following a license agreement with Professors Sredni & Albeck of Bar Ilan University.